Recent data that showed higher OS after exercise in patients with colorectal cancer are reviewed in the context of GU cancer.
The Uromigos
The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.
Latest Episode
Advertisement
Dr. Silke Gillessen joins the show to discuss highlights from the ASCO 2025 Annual Meeting with Brian and Tom.
Dr. Joshua Meeks joins the podcast to give a stellar overview of emerging data in the NMIBC space.
Dr. Gerhardt Attard discusses practice-changing data from AMPLITUDE, and the history of PARP inhibitor use.
Dr. Nick James discusses data from STAMPEDE on the use of AI to predict benefit from ADT + abiraterone.
Dr. Jorge Garcia discusses the process of selecting abstracts for oral presentation.
Dr. Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
The Uromigos: Live and Unplugged 2023
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
Kidney Cancer Discussions
Dr. Viktor Grünwald joins the show to discuss the new data session from the European International Kidney Cancer Symposium.
Returning guest Dr. Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
Dr. Vincent Xu of Dana-Farber Cancer Institute discusses this emerging RCC biomarker and data from the Checkmate 214 trial.
Returning guest Dr. Laurence Albiges discusses novel combos in refractory RCC and gives an update on COSMIC-313.
Dr. Brian Rini’s Disclosures
Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis
Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai
Stock: PTC therapeutics
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.